Due to federal budget constraints, the National Cancer Institute faces significant risk, impacting cancer research funding ...

IGV-001 is an autologous cell immunotherapy with antisense oligonucleotide targeting IGF-1R. In the phase 1b study, IGV-001 ...

The FDA has approved the investigational new drug application of WGc-043, an Epstein-Barr virus-related mRNA cancer vaccine. Epstein-Barr virus is correlated with several malignancies, making this ...

Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in ...

During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at ...

Lopez-Chavez discusses promising new avenues for SCLC treatment, including with an investigational GM1 antibody by Bristol ...

The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free ...

During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient ...

Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive ...

Sima Porten, MD, MPH, discusses the rationale for the phase 3 SunRISe-5 study of TAR-200 in non-muscle invasive bladder ...

Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk ...

Tina Cascone, MD, PhD, discusses who was included in the phase 3 CheckMate-77T trial and the key end points of the study.